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Over the past decade, interest in regenerative medicine and
adult stem cell therapies in sports medicine has expanded
rapidly around the world. With the ability to self-renew and
differentiate into multiple types of cells and tissues, adult
stem cells hold signiﬁcant promise. In sports medicine, basic
science and clinical research is investigating the use of stem
cells in several areas including, but not limited to: osteoar-
thritis,1,2 articular cartilage repair,3,4 anterior cruciate liga-
ment (ACL) reconstruction,5–8 tendon healing,9–12 and
meniscus regeneration.13–15
To the authors’ knowledge, the ﬁrst randomized control
trial on the intra-articular injection of human mesenchymal
stem cells into the knee was recently published, and demon-
strated their safe use and potential ability to regenerate
meniscal tissue.15 A review of clinicaltrials.gov indicates
that inMay 2014, over 45 clinical trials were being conducted
worldwide on the use of stem cells in orthopedic pathologies
of the knee. Interest in the ﬁeld of regenerative medicine
has even prompted elite athletes to travel worldwide to
receive intra-articular therapies such as Regenokine® and
Regenexx®, which are advertised as containing adult stem
cells. With great promise, however, comes potentially great risk.
Safety concerns remain because the process of differentiating
into somanycell and tissue types is notwell understood, and the
means of regulating these pathways are often unknown.
Pluripotent stem cells may hold the greatest therapeutic
potential because they can differentiate into virtually any cell
type. Pluripotent stem cells are isolated in three ways: (1)
directly from human embryos (embryonic stem cells, ESCs),
(2) from cloned embryos through somatic cell nuclear trans-
fer (SCNT), or (3) from adult cells reprogrammed to a plurip-
otent state (induced pluripotent stem cells; IPSCs).16 As
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Abstract In sportsmedicine, adult stem cells are the subject of great interest. Several uses of stem
cells are under investigation including cartilage repair, meniscal regeneration, anterior
cruciate ligament reconstruction, and tendinopathy. Extensive clinical and basic science
research is warranted as stem cell therapies become increasingly common in clinical
practice. In the United States, the Food and Drug Administration (FDA) is responsible for
regulating the use of stem cells through its “Human Cells, Tissues, and Cellular and
Tissue-Based Products” regulations. This report provides a brief overview of FDA
regulation of adult stem cells. Several common clinical case scenarios are then
presented that highlight how stem cells are currently being used in sports medicine
and how current FDA regulations are likely to affect the physicians who use them. In the
process, it explains how a variety of factors in sourcing and handling these cells,
particularly the extent of cell manipulation, will affect what a physician can and cannot
do without ﬁrst obtaining the FDA’s express approval.
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pluripotent stem cell work can involve the creation and
destruction of embryos and the possibility for reproductive
cloning of entire organisms, and raises concerns about un-
controlled growth (such as teratomas), their use has been
complicated by serious ethical concerns and signiﬁcant tech-
nical challenges. This has led to varying regulatory ap-
proaches by different countries. Some regulatory bodies
will allow the use of ESCs derived from discarded embryos
or in vitro fertilization.16 A smaller number will permit the
creation of new ESC lines for research purposes.16 Others ban
SCNT research, limit research to existing cell lines, or ban
pluripotent work altogether. In the United States, research on
ESCs was previously limited because federal funds could not
be used to create new ESC lines. However, this has changed
under the Obama administration.
Although more limited in their ability to differentiate,
multipotent adult stem cells create less ethical and political
controversy, tend to carry less risk, and pose fewer technical
challenges than their pluripotent counterparts. In recent
years, many specialties, including sports medicine and ortho-
pedics, plastic and reconstructive surgery, cardiology, and
ophthalmology, have been increasingly active in researching
and developing adult stem cell therapies. Much of this work
has focused on mesenchymal stem cells (most commonly
bone marrow–derived and also adipose-derived stem cells
[ASCs]). Bone marrow–derived mesenchymal stem cells can
differentiate into several types of connective tissue including
cartilage, bone, tendon, ligament, and muscle.17,18 Other
sources of adult stem cells that have common characteristics,
but are distinctive and reﬂective of their tissue of origin
include synovium, umbilical cord, muscle, and adipose tis-
sue.18,19 Each of these distinctive cell types has shown
varying ability to differentiate into cartilage, bone, muscle,
tendon, ligament, as well as fat.18 Interest in using ASCs in
sports medicine continues to grow as they are readily acces-
sible, abundant, and a reliable source for isolation of adult
stem cells.20,21 To date, however, research on their use in the
ﬁeld of sports medicine has been limited to proof of concept/
basic science studies, case reports, and phase I safety
trials.20,22
In the United States, the growing enthusiasm for using
adult stem cell therapies in sportsmedicine and other areas of
medical practice is often coupled with signiﬁcant legal and
regulatory obstacles to doing so. It is therefore important for
the physician to understand how adult stem cells are regu-
lated in the United States, and how these complex rules are
likely to affect what can and cannot be done in clinical
practice. The aim of this discussion is to explain the Food
and Drug Administration’s (FDA) current regulatory frame-
work in the adult stem cell context and evaluate its impact on
the use of stem cells in the sports medicine today.
Regulation of Adult Stem Cell Therapies in
the United States
The U.S. Food and Drug Administration (FDA) regulates cell
and tissue products as part of its implementation of two
federal laws: the Public Health Service Act (PHSA) and the
Food Drug and Cosmetics Act (FDCA). An adult stem cell is a
“biological product” under the PHSA because like a “thera-
peutic serum, … blood, blood component or derivative, …
protein … or analogous product,” it is “applicable to preven-
tion, treatment or cure of a disease or condition in human
beings.”23 An adult stem cell also falls within the FDCA’s
deﬁnition of a “drug” because it is an “articl[e] intended for
use in the diagnosis, cure, mitigation, treatment or preven-
tion of disease” and “intended to affect the structure or
function of the body ….”24 Finally, stem cells can constitute
a “medical device,”which the FDCA deﬁnes as “any product or
equipment used to diagnose a disease or other conditions, to
cure, to treat or to prevent disease.”25 Products that satisfy
more than one deﬁnition can also function as combination
products.
The FDA oversees cell therapies through its Center for
Biologics Evaluation and Research (CBER) and Center for
Devices and Radiological Health (CDRH). Since 2001, the
FDAhas used a three-tiered, risk-based regulatory framework
to promote the safety and efﬁcacy of human cells, tissues, and
cellular and tissue-based products (HCT/Ps).26 Current good
tissue practices (cGTPs) apply throughout. Otherwise, the
extent of regulation varies directly with the product’s poten-
tial risk, especially with regard to the risk of introduction,
transmission, and spread of communicable disease. Thus,
depending on how a particular cell or tissue product is
categorized, a physician may face relatively simple registra-
tion requirements or be held to the demanding premarketing
approval requirements that bind the likes of Pﬁzer, Merck,
and other global pharmaceutical companies when commer-
cializing a product for mass consumption.
Before examining the regulations more closely, it is
helpful to deﬁne four key terms: manufacturer, establish-
ment, combination with another article, and minimal
manipulation.27 A physician becomes a “manufacturer” of
HCT/Ps by engaging in any or all steps in HCT/P recovery,
processing, storage, labeling, packaging, or distribution. An
“establishment” is a physician’s ofﬁce, clinic, or any place of
business under onemanagement that manufactures HCT/Ps.
As explained later, combining HCT/Ps with other “articles”
can increase safety concerns and thereby increase the degree
of regulatory oversight. For this reason, the regulations
exempt combining the HCT/P with “water, crystalloids, or
a sterilizing, preserving, or storage agent, provided that their
addition poses no additional concerns regarding clinical
safety.”
The most important term, and the most difﬁcult to
determine in practice is “minimal manipulation.” The regu-
lation deﬁnes it separately for structural tissue and cells/
nonstructural tissues,27 and both are relevant to sports
medicine although manipulation of cells and nonstructural
tissues is the focus of this discussion. For structural tissue,
minimal manipulation involves “processing of the HCT/P
[that] does not alter the original relevant characteristics of
the tissue relating to the tissue’s utility for reconstruction,
repair, or replacement.” For cells or nonstructural tissues,
minimalmanipulation is “processing of the HCT/P [that] does
not alter the relevant biological characteristics of cells or
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tissues.” The degree of cell manipulation is critical in deter-
mining where an HCT/P will fall in the following three-tiered
framework.
Category 1: No HCT/P Oversight
Products in this category are not regulated as HCT/Ps because
they are deemed to be of low risk. Category 1 includes
vascularized human organs for transplantation, whole blood
and blood-derived products, and extracted human products
such as collagen and bone marrow that are minimally ma-
nipulated, for homologous use and not combined with an-
other article (except for the purpose of sterilizing, preserving,
or storing).27 By default, Category 1 also includes cells that are
expressly exempted from Categories 2 and 3, described later.
For this discussion, themost signiﬁcant exemption covers “an
establishment that removes HCT/Ps from an individual and
implants such HCT/Ps into the same individual during the
same surgical procedure”28—but again, this applies only if
HCT/Ps are minimally manipulated, for homologous use and
not combinedwith other articles. Physicians or clinicianswho
use Category 1 products must follow cGTPs, but otherwise
need not register as an establishment with the FDA’s CBER or
submit a list of the HCT/Ps used.
Category 2: Section 361 Products with Minimal
Oversight
The FDA views Section 361 products as posing a greater risk
with regard to safety and regulates themmore extensively to
prevent contamination, infection, and disease transmission.
Section 361 products that are commonly used in sports
medicine include bone, cartilage, ligament, tendon, and
skin.29 However, to fall within Section 361, these products
must be:
1. No more than minimally manipulated which, again, for
structural tissue, means preserving the “original relevant
characteristics of the tissue relating to the tissue’s utility
for reconstruction, repair, or replacement”27 and for cells
or nonstructural tissues, prevents a change in the “relevant
biological characteristics of cells or tissues”27 during
processing, storage, etc.
2. Used for a homologous purpose.
3. Combinedwith no other cells, tissues, or articles except for
water, crystalloids, or a sterilizing, preserving, or storage
agent, provided that their addition poses no additional
concerns regarding clinical safety.
4. These products must also have either
a. No systemic effect or otherwise depend on the meta-
bolic activity of living cells for their primary function or
b. A systemic effect or depend on the metabolic activity of
living cells for their primary function, and for
i. Autologous use
ii. Allogeneic use in a ﬁrst- or second-degree blood
relative, or
iii. Reproductive use
For cells and nonstructural tissues, certain methods have
been expressly characterized as minimal manipulation; that
is, as involving no change in cell function or characteristics
during processing, storage, and the like. They include the
following:
• Centrifugation
• Cutting, grinding, or shaping
• Soaking in antibiotic solution
• Sterilization by ethylene oxide treatment or irradiation
• Cell separation
• Lyophilization
• Cryopreservation or freezing
Physicians who use or “manufacture” Section 361 HCT/Ps
must employ cGTPs, register their ofﬁce or clinic as an
“establishment,” and submit an annually updated list of
each HCT/P manufactured to CBER.30,31 They need not obtain
premarketing approval before using the product or follow
current Good Manufacturing Practices (cGMPs) in preparing
them.
Category 3: Section 351’s Extensive Regulation of
HCT/Ps as Biologics and Drugs
Products are most likely to shift from the comparatively
relaxed oversight of Section 361 to the more stringent
requirements of Section 351 if—at least in the FDA’s view—
they present greater risks. While Section 361 focuses on
safety and preventing infection and disease transmission,
Section 351 concentrates on both safety and effectiveness.
For the clinician, this imposes more onerous requirements
(such as cGMPs and premarketing approval) with little dis-
tinction between individuals and small physician practices
versus larger pharmaceutical industries. Thus, cells or proc-
essing methods that fail to satisfy any of Section 361’s
requirements will cast a product into the heavily regulated
Section 351 track.
A product will fall within Section 351 if it is one or more of
the following:
1. More than minimally manipulated, which for cells and
nonstructural tissue means to present a risk of change in
cell morphology, function, expression, or other relevant
biological characteristics during processing, storage, etc.
2. Used for a nonhomologous purpose.
3. Combined with other articles that may pose additional
concerns regarding clinical safety.
4. Have a systemic effect or otherwise rely on the metabolic
activity of living cells for its primary function, and be used
in a context other than autologous use, allogeneic use in a
ﬁrst or second degree relative, or reproductive use.
Like Section 361, Section 351 requires an establishment
to register and ﬁle a list of its HCT/Ps with CBER each year.
The main reason why Section 351 is more problematic in
the clinical setting, however, is that, it also requires the
physician or clinic to complete the burdensome and expen-
sive process of obtaining formal premarket approval from
the FDA. This can involve submitting a New Drug Applica-
tion, an Investigational New Drug Application, Biologics
License Application, or, when dealing with a Section 501k
medical device, a premarket approval application or pre-
market notiﬁcation. Costly and time-consuming controlled
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clinical trials may be needed to establish product safety,
purity, potency, efﬁcacy, and stability. In addition, physi-
cians using Section 351 HCT/Ps must follow the FDA-
prescribed cGMPs and prescription drug labeling require-
ments that govern commercial pharmaceutical manufac-
turers. Without premarket approval, cGMPs, and/or proper
labeling, a Section 351 HCT/P is an “adulterated” and/or
“misbranded” drug and biologic under the FDCA and the
PHSA, respectively. This remains true even if the patient is
being treated with her own cells. Using such adulterated
and misbranded products exposes the physician and the
clinic to FDA sanctions including orders of retention, recall,
destruction of the HCT/P, cessation of manufacturing, and/
or shutdown of the entire facility.32
It must be emphasized that Section 351 applies equally to
autologous and allogeneic use in contrast to Section 361,
which treats autologous and allogeneic use differently. Con-
sequently, treating a patient with a Section 351 HCT/P means
that the physician as “manufacturer” and the ofﬁce, clinic, or
hospital as “establishment” are “marketing” the cell product.
Treatment of this kind requires premarket approval even if
those cells are to be injected into the same patient fromwhich
they were harvested.
Adult Stem Cells in Sports Medicine: The
Physician, the Regulator, and the Courts
The FDA’s authority to promulgate, interpret, and enforce its
three-tiered, risk-based HCT/P regulations was recently test-
ed in the U.S. v. Regenerative Sciences, LLC, where, after years
of litigation, a federal appellate court upheld the agency’s
power to regulate adult stem cells as drugs and biologics.33
The decision demonstrates the longstanding legal principle
that courts will defer to the broad discretion of an agency to
regulate matters within its scope of authority, especially in
matters that demand scientiﬁc expertise. The court therefore
afﬁrmed the FDA’s decision to categorize a mixture of cul-
tured mesenchymal stem cells and doxycycline as a Section
351 product that needed to comport with cGMPs and pre-
scription labeling requirements, and obtain premarketing
approval before it could be used to treat various orthopedic
injuries.
Speciﬁcally, Drs. Christopher Centeno and John Schultz,
through their company Regenerative Sciences and the Colo-
rado-based Centeno-Schultz Clinic, used their “Cultured
Regenexx Procedure” to isolate mesenchymal cells from
bone marrow or synovial ﬂuid, transport them off-site to a
separate laboratory, culture the cells for several weeks (so as
not to involve the “same surgical procedure”), mix themwith
other products including doxycycline and heparin, and trans-
port them back to the clinic where they would be reinjected
into the same patient. The court found that:
1. The Regenexx cell product satisﬁed the statutory deﬁni-
tions of a “drug” under the FDCA and a “biologic” under the
PHSA and, therefore, fell within the FDA’s authority to
regulate HCT/Ps.
2. The Regenexx Procedure could be regulated simultaneous-
ly under state law as the practice of medicine, and under
federal law through the FDA’s HCT/P regulations. Although
derived from bone marrow (often exempted from HCT/P
oversight under Category 1) and intended for autologous
use (often covered by Section 361), the Regenexx cell
product was properly regulated under Section 351 be-
cause it wasmore thanminimallymanipulated insofar as it
was: cultured; exposed to different temperatures and
media; and “combined” with other “articles” (including
doxycycline and heparin)—all of which could affect rele-
vant biological characteristics of the cell, including cell
function, and differentiation; and, with regard to doxycy-
cline, cause infection, severe allergic reaction, or other
adverse events.
3. Under Section 351, the physicians as “manufacturers” and
the clinic as an “establishment” were required to:
a. Register the establishment with CBER
b. Submit an annually updated list of all HCT/Ps used (or
“marketed”) to CBER
c. Obtain formal premarket approval before using (i.e.,
“marketing”) the cell product to treat patients—even
when the cells were for autologous use
d. Fulﬁll all requirements regarding manufacturing/
cGMPs, processing, and packaging
e. Fulﬁll all labeling requirements for a prescription drug,
including labeling it as “Rx only” and providing ade-
quate “directions under which the layman can use a
drug safely and for the purposes for which it is
intended.”34
4. By violating Section 351’s requirements for manufactur-
ing, processing, and premarket approval, the physicians
and clinic had engaged in the unlawful distribution of an
“adulterated drug.”
5. They had also distributed a “misbranded drug” because
Section 351’s labeling requirements had not been satisﬁed.
6. The FDA was therefore within its authority to enforce its
HCT/P regulations for Section 351 cell products which, in
this case, resulted in permanently enjoining the physicians
and clinic from using the Regenexx procedure in the
United States to treat orthopedic injuries.
Impact of HCT/P Regulations on Sports
Medicine Going Forward
To ensure compliance with these complex regulations and
avoid the kinds of sanctions and expensive litigation that
ensued in the Regenerative Sciences case, a physician must
evaluate whether a particular procedure involves a less
regulated Category 1 “non-HCT/P,” a Category 2/Section
361 HCT/P, or a Category 3/heavily regulated Section 351
product. Unfortunately, this can be quite difﬁcult for a variety
of reasons. Under the HCT/P regulations, a Section 361 versus
Section 351 product may result from the same substance
being subjected to different conditions that—again, at least in
the FDA’s view—present different degrees of risk so as to
warrant different levels of oversight. The physician must
therefore remember that how a particular adult stem cell
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therapy is categorized and regulated will depend, at least in
part, on:
• The source of that cell (e.g., bone marrow vs. fat)
• The degree of cell manipulation in isolating or processing
that cell (e.g., centrifuge vs. culture)
• The homologous or nonhomologous use of that cell, and
• The ultimate recipient of that cell (autologous vs.
allogeneic).
Accordingly, the same cell from the same source in the
same donor may be a Category 1/non-HCT/P or Category 2/
Section 361 product if it is minimally manipulated; homolo-
gous; not combined with articles involving safety concerns;
and for autologous use, allogeneic use for a close blood
relative or reproductive use. Alternatively, that same cell
from the same source in the same donor may qualify as a
heavily regulated Category 3/Section 351 HCT/P if it is more
than minimally manipulated, and used in a way that is
nonhomologous, nonreproductive and/or allogeneic beyond
a ﬁrst- or second-degree relative.
Determining which regulatory track applies is also difﬁ-
cult because as therapies evolve and technologies improve,
deﬁnitional ambiguities remain unresolved. In this respect,
one of the most difﬁcult challenges is deﬁning what qualiﬁes
as minimal versus more than minimal manipulation because
this distinction is a key factor in determining whether
premarketing approval is required under Section 351. There-
fore, to evaluate the Section 361 versus Section 351 divide as
it presents in clinical practice and illustrate how FDA over-
sight will increase with increasing degrees of cell manipula-
tion, we present the following examples of manipulating
adult stem cells for use in sports medicine:
1. Isolation by centrifugation
2. Stromal-vascular fracture with collagenase
3. Culture and expansion
In the process, we also discuss the impact of the following:
a. Bone marrow versus adipose-derived cells
b. Homologous versus nonhomologous use
c. Autologous versus allogeneic use
d. Harvested, processed, and reinjected during “the same
surgical procedure”
e. Harvested, processed, and reinjected in the United States
versus another country.
Before proceeding, wemust emphasize that our evaluation
of the following hypotheticals is predictive, not deﬁnitive. To
date, the technical and therapeutic capabilities of researchers
and physicians have outpaced the ability of regulators to
respond to the particular challenges and opportunities of
adult stem cell therapies (especially for autologous use).
Existing regulations were created to address other kinds of
clinical applications and often provide an awkward ﬁt for
adult stem cell therapies. With regard to the procedures
discussed later, there is little in the way of actual agency
enforcement or formal guidance. As a result, we have had to
rely on the few resources that do exist: the HCT/P regulations,
the Regenerative Sciences litigation, and the FDA’s draft and
ﬁnal guidance documents andwarning letters. In this context,
however, the agency’s ﬁnalized guidance documents are few
to none and guidance documents are, by deﬁnition, merely
suggestive and subject to change. Looking to tentative draft
guidances to predict future regulatory enforcement is even
more problematic, especially where the agency has yet to
evaluate public comments on its most recent draft guidances.
Despite these uncertainties, we offer our best prediction of
how the FDA would view the following scenarios—some of
which differ only to a small degree. We include them because
one small change in clinical practice can unleash a signiﬁcant
jump in regulatory demands.
Application of Current FDA Regulations to
Adult Stem Cell Use in Sports Medicine
1A. Intraoperative Isolation of Autologous Bone
Marrow–Derived Stem Cells by Centrifugation and
Injection
Using cells under these conditions is likely to qualify as a
Category 1 “non-HCT/P” because the cell product involves a
speciﬁcally exempted product (bone marrow), is autologous,
used for a homologous purpose, and not combinedwith other
articles. Moreover, the FDA has long viewed centrifugation as
minimalmanipulation. Recent draft guidances,35–37 however,
have created some confusion as towhether it will continue to
do so. In our view, it is likely that the ambiguous wording of
these draft guidances will be clariﬁed to continue to charac-
terize centrifugation and other means of physical separation
as forms of minimal manipulation. Under these circumstan-
ces, this cell product should be exempted from oversight
under Category I. Therefore, clinicians canmost likely use this
cell product without having to comply with either Section
361’s requirements to register as an establishment and list all
HCT/Ps used with CBER, or satisfy Section 351’s additional
requirements regarding premarket approval, cGMPs, and
labeling.
Should the bone marrow and/or same surgical procedure
exemptions not apply so as to disqualify the cell product
from Category 1, it should at most be covered by Category
2/Section 361 because it is still autologous, used for a
homologous purpose, and most likely not more than mini-
mally manipulated.
1B. Intraoperative Isolation of Autologous Adipose-
Derived Stem Cells by Centrifugation and Injection of
Stromal Vascular Fraction
Current regulations treat stem cells derived from bone mar-
row and fat differently. Bone marrow–derived stem cells
explicitly qualify as Category 1/non-HCT/Ps but only if they
are for autologous and homologous use, minimally manipu-
lated, not combined with articles that raise safety concerns,
and have no systemic effect. Adipose tissue–derived stem
cells are not expressly exempted and, therefore, are typically
regulated as Category 2/Section 361 or Category 3/Section
351 products depending on the level of manipulation, in-
tended use, etc. A recent draft guidance would subject adi-
pose stem cells, which are obviously cellular, to the structural
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as opposed to cellular deﬁnition of minimal manipula-
tion.35–37 This immediately incited a broad array of concerns
among clinicians that may sway the FDA to alter its position.
The scenario described here, however, should involve the
kind of “same surgical procedure” that is exempt from
Sections 361 and 351 because—again, presuming the FDA
clariﬁes or dismisses its recent draft guidances—it most likely
entails minimal manipulation with homologous and autolo-
gous use, and is harvested, processed, and reinjected without
interruption of the overall process. For this and any clinical
fact situation, a question could be raised as to whether using
an adipocyte technically qualiﬁes as homologous use as the
cell source—fat—arguably has little to do with the object of
repair. To date, this has not been a regulatory focus but the
FDA has signaled that it will examine this more closely. For
now, this procedurewouldmost likely fall within Category 1’s
same surgical procedure exemption as the cells are with-
drawn, centrifuged, separated, and reinjected into the same
patient, and completed within the same room during a time
frame of several hours. Under Category 1, the treatment could
go forward with no need to register the establishment,
submit lists of HCT/Ps, obtain premarket approval or follow
manufacturing or labeling requirements.
At most, it is likely to fall within Category 2’s relatively
minimal Section 361 oversight as cell separation is accom-
plished through centrifugation, a form of minimal manipula-
tion, and the resulting product will be used autologously.
Should Section 361 control, the physician as “manufacturer”
would need to register the ofﬁce, clinic, or hospital as an
“establishment” with CBER, and also provide CBER with an
annually updated list of all HCT/Ps used at that establishment.
2. Intraoperative Selective Isolation of Adipose-
Derived Stem Cells through Treatment of the Stromal-
Vascular Fraction with Collagenase and Albumin and
Injection
The aim of adding collagenase is to produce a higher yield of
stem cells than would otherwise be obtained by centrifuge
alone. The FDA has not formally deﬁned whether or not this
constitutes more than minimal manipulation. However, sev-
eral agency warning and nonbinding guidance documents
issued by the FDA indicate that introducing an enzyme to
increase yield may qualify as more than minimal manipula-
tion as it may pose a risk of changing cell behavior or
characteristics.
Should the introduction of collagenase be viewed as
minimal manipulation, the procedure will fall within Catego-
ry 2/Section 361 and require establishment registration and
HCT/P listing with CBER. It must be emphasized that when
evaluating risk in order to predict a procedure’s regulatory
status, what matters most is how the FDA views a procedure.
Consequently, even if a physician or group of physicians
deems the introduction of collagenase to present little risk
to cell morphology and behavior, the FDA has broad discre-
tion to disagree. Its informal statements to date suggest that it
will characterize SVF with collagenase as more than minimal
manipulation, thereby triggering Category 3’s Section 351
requirements. As a result, the clinic/establishment has two
choices. First, it can attempt to persuade the FDA to classify
this or any speciﬁc procedure asminimalmanipulation under
Category 2/Section 361. Unless that effort succeeds, its second
and only remaining option is to abide by Section 351 and
complete all of the following:
• Register with CBER
• Submit lists of HCT/Ps used to CBER
• Follow cGMPs for pharmaceutical drugs
• Follow prescription drug labeling requirements
• Undertake the time and expense involved in obtaining
premarket approval (including controlled clinical trials)
Failing to satisfy any of these requirements will expose the
physician and clinic to increasingly stiff sanctions, ranging
from site inspections and warning letters to a permanent
injunction of the procedure or a shutdown of the entire
establishment.32
3A. Harvest, Culture, and Expansion of Autologous
Bone Marrow–Derived Stem Cells with Delayed
Injection in the United States
These facts parallel those of U.S. v. Regenerative Sciences,
LLC,35 as discussed earlier. That case makes it fairly certain
that, absent full satisfaction of Section 351’s premarketing
approval, cGMPs and labeling requirements, this patient
would have to leave the United States to be treated with cells
that have been cultured and expanded. Thiswould apply even
though the cells are her own. As previously discussed, the FDA
has long viewed centrifugation alone as minimal manipula-
tion and will hopefully clarify recent draft guidelines to
maintain this position. In Regenerative Sciences, however,
removing the cells from the place of treatment, culturing, and
expanding them over several weeks, and adding such “ar-
ticles” as doxycycline and heparin to the culture product and
returning them to the clinic for use in the patient was, in the
FDA’s view, clearly more than minimal manipulation as these
measures escalated the risk of contamination, infection,
disease transmission, and change in the cell’s composition
and behavior. Physicians who use this or similar processes
should comply with Section 351, shift to alternative Category
1 or Category 2 methods of processing, or conduct this work
outside the United States.
3B. Harvest of Autologous BoneMarrow–Derived Stem
Cells in the United States with Culture, Expansion, and
Delayed Injection Overseas
Foreign travel for the sake of undergoing treatment may
reduce the likelihood of FDA enforcement, but it does not
necessarily eradicate it. Harvesting cells in the United States
may be enough, and preparing the cell product in the United
States should bemore than enough to subject the physician to
Section 351 premarketing approval requirements—and pen-
alties for noncompliance—even if the actual administration of
the resulting cell product occurs offshore. A physician should
err on the side of caution and presume that performing even a
small step in the sequence between cell harvest and reinjec-
tion will support the FDA’s jurisdiction to enforce its HCT/P
regulations in full.
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3C. Harvest, Culture, and Expansion of Autologous
Bone Marrow–Derived Stem Cells with Delayed
Injection Overseas
In this case, the entire process of harvesting, culturing,
expanding, and injecting the patient’s own stem cells occurs
overseas. This is beyond the scope of FDA jurisdiction. How-
ever, through its formal Global Initiative, the FDA is currently
forging collaborations with countries around the world to
harmonize regulations. The central goal of this effort is to
build regulatory capacity and develop international stand-
ards so that all the countries will employ similar approaches
when regulating medical drugs and devices, including adult
stem cell therapies.
3D. Allogeneic Bone Marrow–Derived Stem Cell
Harvest, Culture, Expansion, and Injection
Bone marrow-derived autologous stem cells are typically
harvested from the iliac crest. The bone marrow aspirate is
then centrifuged, stem cells are isolated and then injected
into the same patient’s injury site. In contrast, allogeneic stem
cells are isolated from a donor other than the patient and then
injected into the patient’s injury site. If the allogeneic donor is
a ﬁrst- or second-degree blood relative, the proceduremay be
treated as if it were autologous, meaning that it could qualify
for minimal Section 361 oversight if it is also homologous and
not more thanminimally manipulated. The clinic would need
to register as an establishment and submit HCT/P lists to
CBER, but it would not need to follow cGMPs or labeling
requirements, or obtain premarket approval.
A donor other than a ﬁrst- or second-degree relative would
shift this procedure into the realm of Section 351. Consequent-
ly, in addition to Section 361’s registration and listing require-
ments, the physician/manufacturer and clinic/establishment
would be required to fulﬁll cGMPs and labeling requirements
for prescription drugs, and obtain formal premarket approval
before using the cell product to treat a patient.
Future of Adult Stem Cell Therapies in Sports
Medicine
The current enthusiasm for the use of adult stem cells in
sports medicine will surely grow as the basic science and
clinical applications advance. At the same time, there is great
confusion about the meaning and enforcement of the FDA’s
complex scheme for regulating stem cell therapies—and this
confusion will also grow as therapeutic options expand. It is
therefore imperative that the sports medicine physician be
familiar with current regulations; remain mindful that reg-
ulations evolve over time regarding both content and inter-
pretation; and remember that the FDA’s rationale is not
always obvious to those who are regulated.
Thus, when dealing with HCT/P regulations, the physician
would be wise to err on the side of caution: assume that a
regulation applies, and assume that the FDA will be risk-
adverse in its interpretation and enforcement (particularly
with regard tominimal vs. more thanminimalmanipulation).
Furthermore, given the great promise of cell therapies, the
complexity of their regulation, the ease of derailing from the
Section 361 track into Section 351, and the high stakes for
noncompliance, obtaining regulatory updates from an attor-
ney or compliance ofﬁcer is not just beneﬁcial, but increas-
ingly necessary. In this way, physicians can focus their
resources on counseling patientswho need themore effective
and less invasive treatments that adult stem cells can offer.
Failing to seek regulatory guidance sooner rather than later
does not avoid risk; it creates its own risk—one that is
signiﬁcant, probably expensive, and largely avoidable.
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